1. Scrip
  2. >>Business

VC Roundup: Relay Raises $57m To Seek Drug Targets Among Proteins In Motion

 
• By Mandy Jackson

Relay launched with $57m to develop its novel technology platform for drug discovery based on protein motion with an initial focus on therapies for genetically defined cancers.

Alexis Borisy Relay Therapeutics
Relay Executive Chairman and Interim CEO Alexis Borisy • Source: Relay Therapeutics

Relay Therapeutics has launched with $57m in Series A venture capital to identify new drug targets and to find new ways of addressing difficult targets by studying proteins in motion rather than looking at static images.

“If a picture is worth a thousand words, a video is worth a thousand pictures,” Relay’s Executive Chairman and Interim...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.